Enhancing patient navigation to improve intervention session attendance and viral load suppression of persons with HIV and substance use: a secondary post hoc analysis of the Project HOPE study

Maxine Stitzer, Tim Matheson, Colin Cunningham, James L Sorensen, Daniel J Feaster, Lauren Gooden, Alexis S Hammond, Heather Fitzsimons, Lisa R Metsch, Maxine Stitzer, Tim Matheson, Colin Cunningham, James L Sorensen, Daniel J Feaster, Lauren Gooden, Alexis S Hammond, Heather Fitzsimons, Lisa R Metsch

Abstract

Background: Interventions are needed to improve viral suppression rates among persons with HIV and substance use. A 3-arm randomized multi-site study (Metsch et al. in JAMA 316:156-70, 2016) was conducted to evaluate the effect on HIV outcomes of usual care referral to HIV and substance use services (N = 253) versus patient navigation delivered alone (PN: N = 266) or together with contingency management (PN + CM; N = 271) that provided financial incentives targeting potential behavioral mediators of viral load suppression.

Aims: This secondary analysis evaluates the effects of financial incentives on attendance at PN sessions and the relationship between session attendance and viral load suppression at end of the intervention.

Methods: Frequency of sessions attended was analyzed over time and by distribution of individual session attendance frequency (PN vs PN + CM). Percent virally suppressed (≤200 copies/mL) at 6 months was compared for low, medium and high rate attenders. In PN + CM a total of $220 could be earned for attendance at 11 PN sessions over the 6-month intervention with payments ranging from $10 to $30 under an escalating schedule.

Results: The majority (74%) of PN-only participants attended 6 or more sessions but only 28% attended 10 or more and 16% attended all eleven sessions. In contrast, 90% of PN + CM attended 6 or more visits, 69% attended 10 or more and 57% attended all eleven sessions (attendance distribution χ2[11] = 105.81; p < .0001). Overall (PN and PN + CM participants combined) percent with viral load suppression at 6-months was 15, 38 and 54% among those who attended 0-5, 6-9 and 10-11 visits, respectively (χ2(2) = 39.07, p < .001).

Conclusion: In this secondary post hoc analysis, contact with patient navigators was increased by attendance incentives. Higher rates of attendance at patient navigation sessions was associated with viral suppression at the 6-month follow-up assessment. Study results support use of attendance incentives to improve rates of contact between service providers and patients, particularly patients who are difficult to engage in care. Trial Registration clinicaltrials.govIdentifier: NCT01612169.

Keywords: Contingent incentives; HIV health care; HIV substance users; Patient navigation; Session attendance; Vial suppression.

Figures

Fig. 1
Fig. 1
The contrasting distribution of PN visit attendance for participants in the PN (N = 266) and PN + CM (N = 271) treatment groups. Bars indicate the percentage of participants in the designated treatment group who achieved each total number of PN visits from 0 to 11 during a 6-month intervention. Incentives were available on an escalating scale starting at $10 and increasing to $30 per visit; PN + CM could earn a total of $220 for attending all visits
Fig. 2
Fig. 2
shows mean number of PN visits attended per month during the 6-month intervention for PN (N = 266) and PN + CM (N = 271) participants
Fig. 3
Fig. 3
The percent of all participants collapsed across PN and PN + CM (N = 508 due to missing viral load data) with suppressed viral load (≤200 copies/mL) at the 6-month assessment as a function of PN visits attended. Number of visits attended has been divided into 3 functional categories: low (0–5 visits; N = 78), moderate (6–9 visit; N = 169) and high (10–11 visits; N = 261)

References

    1. Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, Nijhawan AE, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316:156–170. doi: 10.1001/jama.2016.8914.
    1. Milward J, Lynskey M, Strang J. Solving the problem of non-attendance in substance abuse services. Drug Alcohol Rev. 2014;33:625–636. doi: 10.1111/dar.12194.
    1. Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88:948–952. doi: 10.1016/j.lfs.2010.09.025.
    1. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163:412–420. doi: 10.1093/aje/kwj059.
    1. Buchacz K, Baker RK, Moorman AC, Richardson JT, Wood KC, Holmberg SD, Brooks JT. HIV Outpatient Study (HOPS) Investigators Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDS. 2008;2008(22):1345–1354.
    1. Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112:178–193. doi: 10.1016/j.drugalcdep.2010.06.014.
    1. Bassett IV, Wilson D, Taaffe J, Freedberg KA. Financial incentives to improve progression through the HIV treatment cascade. HIV AIDS. 2015;10:451–463.
    1. Thornton RL. The demand for, and impact of, learning HIV status. Am Econ Rev. 2008;98:1829–1863. doi: 10.1257/aer.98.5.1829.
    1. Mallotte KC, Rhodes F, Mais KE. Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health. 1998;88:792–796. doi: 10.2105/AJPH.88.5.792.
    1. Mallotte KC, Hollingshead JR, Rhodes F. Monetary versus nonmonetary incentives for TB skin test reading among drug users. Am J Prev Med. 1999;16:182–188. doi: 10.1016/S0749-3797(98)00093-2.
    1. Weaver T, Metrebian N, Hellier J, Pilling S, Charles V, Little N, Poovendran D, Mitcheson L, Ryan F, Bowden-Jones O, Dunn J, Glasper A, Finch E, Strang J. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Lancet. 2014;384:153–163. doi: 10.1016/S0140-6736(14)60196-3.
    1. Corrigan JD, Bogner J, Lamb-Hart G, Heinemann AW, Moore D. Increasing substance abuse treatment compliance for persons with traumatic brain injury. Psychol Addict Behav. 2005;19:131–139. doi: 10.1037/0893-164X.19.2.131.
    1. Fitzsimons H, Tuten M, Borsuk C, Lookatch S, Hanks L. Clinician-delivered contingency management increases engagement and attendance in drug and alcohol treatment. Drug Alcohol Depend. 2015;152:62–67. doi: 10.1016/j.drugalcdep.2015.04.021.
    1. Petry NM, Martin B, Finocche C. Contingency management in group treatment: a demonstration project in an HIV drop-in center. J Subst Abuse Treat. 2001;21:89–96. doi: 10.1016/S0740-5472(01)00184-2.
    1. Solomon SS, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS, Balakrishnan P, Mehta SH, Solomon S, Lucas GM. Voucher incentives improve linkage to and retention in care among HIV-infected drug users in Chennai, India. Clin Infect Dis. 2014;59:589–595. doi: 10.1093/cid/ciu324.
    1. Branson CE, Barbuti AM, Clemmey P, Herman L, Bhutia P. A pilot study of low-cost contingency management to increase attendance in an adolescent substance abuse program. Am J Addict. 2012;21:126–129. doi: 10.1111/j.1521-0391.2011.00204.x.
    1. Jones HE, Haug N, Silverman K, Stitzer M, Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend. 2001;61:297–306. doi: 10.1016/S0376-8716(00)00152-6.
    1. Ledgerwood DM, Alessi SM, Hanson TH, Godley MD, Petry NM. Contingency management for attendance to group substance abuse treatment administered by clinicians in community clinics. J Appl Behav Anal. 2008;41:517–526. doi: 10.1901/jaba.2008.41-517.
    1. Petry NM, Martin B, Simcic F. Prize reinforcement contingency management for cocaine dependence: integration with group therapy in a methadone clinic. J Consult Clin Psychol. 2005;2005(73):354–359. doi: 10.1037/0022-006X.73.2.354.
    1. Petry NM, Weinstock J, Alessi SM. A randomized trial of contingency management delivered in the context of group counseling. J Consult Clin Psychol. 2011;79:68–96. doi: 10.1037/a0024813.
    1. Petry NM, Barry D, Alessi SM, Rounsaville BJ, Carroll KM. A randomized trial adapting contingency management targets based on initial abstinence status of cocaine-dependent patients. J Consult Clin Psychol. 2012;80:276–285. doi: 10.1037/a0026883.
    1. Sigmon SC, Stitzer ML. Use of a low-cost incentive intervention to improve counseling attendance among methadone-maintained patients. J Subst Abuse Treat. 2005;29:253–258. doi: 10.1016/j.jsat.2005.08.004.
    1. Kidorf M, Brooner RK, Gandotra N, Antoine D, King VL, Peirce J, Ghazarian S. Reinforcing integrated psychiatric service attendance in an opioid-agonist program: a randomized and controlled trial. Drug Alcohol Depend. 2013;133:30–36. doi: 10.1016/j.drugalcdep.2013.06.005.
    1. Bradford JB, Coleman S, Cunningham W. HIV system navigation: an emerging model to improve HIV care access. AIDS Patient Care STD. 2007;21(Suppl 1):49–58.
    1. Dohan D, Schrag D. Using navigators to improve care of underserved patients. Cancer. 2005;104:848–855. doi: 10.1002/cncr.21214.
    1. Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, Del Rio C, Strathdee S, Holmberg SD. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19:423–431. doi: 10.1097/01.aids.0000161772.51900.eb.
    1. Cabral HJ, Tobias C, Rajabiun S, Sohler N, Cunningham C, Wong M, Cunningham W. Outreach program contacts: do they increase the likelihood of engagement and retention in HIV primary care for hard-to-reach patients? AIDS Patient Care STD. 2007;21(Suppl 1):59–67.
    1. Stitzer M, Calsyn D, Matheson T, Sorensen J, Gooden L, Metsch L. Development of a multi-target contingency management intervention for HIV positive substance users. J Subst Abuse Treat. 2017;72:66–71. doi: 10.1016/j.jsat.2016.08.018.
    1. Bellera CA, Julien M, Hanley JA. Normal approximations to the distribution of the Wilcoxon statistics: Accurate to what N? Graphical insights. J Stat Educ. 2010;18:1–17.
    1. Petry NM. Contingency management for substance abuse treatment. A guide to implementing this evidence-based practice. NY, London: Routledge Taylor & Francis Group; 2012.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa